162 related articles for article (PubMed ID: 37490120)
1. Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors-a nationwide retrospective cohort study.
Hu WS; Lin CL
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):575-581. PubMed ID: 37490120
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter-2 inhibitor in risk of sepsis/septic shock among patients with type 2 diabetes mellitus-a retrospective analysis of nationwide medical claims data.
Hu WS; Lin CL
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1623-1631. PubMed ID: 37698621
[TBL] [Abstract][Full Text] [Related]
4. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
[TBL] [Abstract][Full Text] [Related]
5. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
Kashiwagi A; Shoji S; Kosakai Y; Koga T; Asakawa K; Rokuda M
J Diabetes Investig; 2023 Mar; 14(3):404-416. PubMed ID: 36515129
[TBL] [Abstract][Full Text] [Related]
6. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
Gao X; Zhang N; Lu L; Gao T; Chou OHI; Wong WT; Chang C; Wai AKC; Lip GYH; Zhang Q; Tse G; Liu T; Zhou J
Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):103-117. PubMed ID: 37962962
[TBL] [Abstract][Full Text] [Related]
7. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
[TBL] [Abstract][Full Text] [Related]
8. Diabetic patients with and without sodium-glucose cotransporter-2 inhibitors use and cataract risk: real-world observational investigation.
Hu WS; Lin CL
Acta Diabetol; 2023 Jul; 60(7):981-987. PubMed ID: 37083962
[TBL] [Abstract][Full Text] [Related]
9. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study.
Ha KH; Kim DJ; Choi YJ
J Diabetes Investig; 2022 Jun; 13(6):986-996. PubMed ID: 35132815
[TBL] [Abstract][Full Text] [Related]
11. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study.
Jeong HE; Park S; Noh Y; Bea S; Filion KB; Yu OHY; Jang SH; Cho YM; Yon DK; Shin JY
BMC Med; 2023 Feb; 21(1):47. PubMed ID: 36765407
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea.
Hwang HJ; Kim M; Jun JE; Yon DK
Sci Rep; 2023 Dec; 13(1):21756. PubMed ID: 38066029
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.
Chung CT; Lakhani I; Chou OHI; Lee TTL; Dee EC; Ng K; Wong WT; Liu T; Lee S; Zhang Q; Cheung BMY; Tse G; Zhou J
Cancer Med; 2023 Jun; 12(11):12299-12315. PubMed ID: 37148547
[TBL] [Abstract][Full Text] [Related]
16. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
[TBL] [Abstract][Full Text] [Related]
17. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.
Mui JV; Li L; Chou OHI; Azfar N; Lee A; Hui J; Lee S; Tse G; Zhou J
Acta Diabetol; 2023 Jul; 60(7):917-927. PubMed ID: 37000300
[TBL] [Abstract][Full Text] [Related]
18. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
[TBL] [Abstract][Full Text] [Related]
19. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
Zhou J; Liu X; Chou OH; Li L; Lee S; Wong WT; Zhang Q; Chang C; Liu T; Tse G; Jing F; Cheung BMY
Rheumatology (Oxford); 2023 Apr; 62(4):1501-1510. PubMed ID: 36066415
[TBL] [Abstract][Full Text] [Related]
20. Decreased risk of renal cell carcinoma in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
Chiu CH; Wang WY; Chen HY; Liao PL; Jong GP; Yang TY
Cancer Sci; 2024 Jun; 115(6):2059-2066. PubMed ID: 38572526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
